Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis.
Ehlers L, Askling J, Bijlsma HW, Cid MC, Cutolo M, Dasgupta B, Dejaco C, Dixon WG, Feltelius N, Finckh A, Gilbert K, Mackie SL, Mahr A, Matteson EL, Neill L, Salvarani C, Schmidt WA, Strangfeld A, van Vollenhoven RF, Buttgereit F. Ehlers L, et al. Among authors: askling j. Ann Rheum Dis. 2019 Sep;78(9):1160-1166. doi: 10.1136/annrheumdis-2018-214755. Epub 2019 Mar 21. Ann Rheum Dis. 2019. PMID: 30898837 Review.
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, van Vollenhoven RF, Klareskog L. Askling J, et al. Ann Rheum Dis. 2007 Oct;66(10):1339-44. doi: 10.1136/ard.2006.062760. Epub 2007 Jan 29. Ann Rheum Dis. 2007. PMID: 17261532 Free PMC article.
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L. Askling J, et al. Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941. Arthritis Rheum. 2009. PMID: 19877027 Free article.
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.
Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A. Curtis JR, et al. Among authors: askling j. Semin Arthritis Rheum. 2010 Aug;40(1):2-14.e1. doi: 10.1016/j.semarthrit.2010.03.003. Semin Arthritis Rheum. 2010. PMID: 20674669 Free PMC article.
Ten years with biologics: to whom do data on effectiveness and safety apply?
Simard JF, Arkema EV, Sundström A, Geborek P, Saxne T, Baecklund E, Coster L, Dackhammar C, Jacobsson L, Feltelius N, Lindblad S, Rantapää-Dahlqvist S, Klareskog L, van Vollenhoven RF, Neovius M, Askling J. Simard JF, et al. Among authors: askling j. Rheumatology (Oxford). 2011 Jan;50(1):204-13. doi: 10.1093/rheumatology/keq326. Epub 2010 Nov 16. Rheumatology (Oxford). 2011. PMID: 21084326
Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries.
Zavada J, Dixon WG, Askling J; EULAR Study group on Longitudinal Observational Registers and Drug Studies. Zavada J, et al. Among authors: askling j. Ann Rheum Dis. 2014 Mar;73(3):628. doi: 10.1136/annrheumdis-2013-204102. Epub 2013 Sep 20. Ann Rheum Dis. 2014. PMID: 24058015 No abstract available.
382 results